Original Research

Prevalence of serum Aspergillus galactomannan positivity among immunocompromised patients with suspected invasive aspergillosis at a tertiary care hospital

Monika Devnani, Nazneen Pathan, Malvika Sharma, Aruna Vyas, Pooja Choudhary, Sidhya Choudhary
African Journal of Laboratory Medicine | Vol 15, No 1 | a3090 | DOI: https://doi.org/10.4102/ajlm.v15i1.3090 | © 2026 Monika Devnani, Nazneen Pathan, Malvika Sharma, Aruna Vyas, Pooja Choudhary, Sidhya Choudhary | This work is licensed under CC Attribution 4.0
Submitted: 03 November 2025 | Published: 14 October 2026

About the author(s)

Monika Devnani, Department of Microbiology, Sawai Man Singh Medical College, Jaipur, India
Nazneen Pathan, Department of Microbiology, Sawai Man Singh Medical College, Jaipur, India
Malvika Sharma, Department of Microbiology, Sawai Man Singh Medical College, Jaipur, India
Aruna Vyas, Department of Microbiology, Sawai Man Singh Medical College, Jaipur, India
Pooja Choudhary, Department of Microbiology, Sawai Man Singh Medical College, Jaipur, India
Sidhya Choudhary, Department of Microbiology, Sawai Man Singh Medical College, Jaipur, India

Abstract

Background: Invasive aspergillosis (IA) is a major opportunistic fungal infection in immunocompromised patients. Serum Aspergillus galactomannan (GM) is an adjunctive marker in suspected IA.
Objective: To determine the prevalence of serum GM positivity and associated risk factors among immunocompromised patients with clinical suspicion of IA.
Methods: A cross-sectional observational study was conducted among 200 immunocompromised patients clinically suspected of IA at a tertiary hospital in Jaipur, India, from July 2023 to December 2023. Serum GM was tested using the Platelia™ Aspergillus GM enzyme immunoassay. Index values < 0.50 were considered negative, ≥ 0.50 positive, and 0.45–0.49 borderline. Demographic and clinical risk factors were recorded from clinical and laboratory records and analysed using chi-square test and multivariate regression.
Results: Among 200 patients, 98 (49.0%) were GM positive, 92 (46.0%) negative, and 10 (5.0%) borderline. On multivariate analysis, neutropenia was the strongest independent predictor of GM positivity, followed by tuberculosis and lung disease. HIV infection was more frequent among GM positive patients but was not independently associated after adjustment.
Conclusion: Serum GM positivity was high among immunocompromised patients with clinically suspected IA. Neutropenia was the strongest independent predictor of GM positivity, while tuberculosis and lung disease were also independently associated. Serum GM may aid evaluation when interpreted with clinical, radiological and microbiological findings. As confirmatory methods were not available for all patients, this study does not establish diagnostic accuracy of the assay.
What this study adds: This study provides data on the prevalence of serum GM positivity among immunocompromised patients with suspected IA in Rajasthan, India. Neutropenia, tuberculosis and chronic lung disease were independently associated with GM positivity, supporting the use of serum GM assay in high-risk patients.


Keywords

invasive aspergillosis; galactomannan antigen; neutropenia; tuberculosis; HIV infection; fungal diagnostics; immunocompromised

Sustainable Development Goal

Goal 9: Industry, innovation and infrastructure

Metrics

Total abstract views: 730
Total article views: 375


Crossref Citations

No related citations found.